New Research on GLP-1 Weight Loss Drugs Offers Reassurance—and New Questions—About Mental Health, Houston Experts Say
As more Houstonians turn to GLP-1 medications for weight loss and metabolic health, new research is offering something many patients and families have been waiting for: reassurance.
With one in eight Americans now reporting use of GLP-1 drugs, according to KFF, these medications—commonly prescribed for diabetes and increasingly for weight management—are becoming part of everyday life in communities across Greater Houston. Now, a newly published study in The Lancet Psychiatry is helping answer a growing question: what do these drugs mean for mental health?
For patients navigating both physical and emotional health challenges, the findings could shape conversations with doctors, influence treatment decisions, and bring a sense of clarity to a rapidly evolving area of medicine.
New Study Finds No Link to Worsening Mental Health
The large-scale study, which analyzed data from more than 95,000 individuals with depression or anxiety, found that GLP-1 receptor agonists were not associated with worsening mental illness. In fact, some medications in the class were linked to improved outcomes.
Researchers observed that certain GLP-1 drugs—particularly semaglutide and liraglutide—were associated with lower risks of worsening depression, anxiety, and even substance use disorders . The study also found a reduced risk of self-harm among users overall.
Importantly, the research used a within-individual design, meaning patients were compared to themselves over time, strengthening the reliability of the findings.
Still, researchers emphasized that the study is observational, meaning it shows associations—not direct cause and effect.
Houston Methodist Specialists See Encouraging Signals
For local providers, the findings align with what they are beginning to observe in clinical settings.
Janelle Jakobi, an obesity medicine specialist and bariatric physician assistant at Houston Methodist Willowbrook Hospital, said the research reflects the broader impact these medications may have on the body.
“These medications don’t just affect weight,” she said. “They also influence parts of the brain involved in appetite, reward and inflammation. When someone’s metabolic health improves, it may also positively affect mood and impulse control.”
Jakobi noted that the most significant mental health improvements appeared in patients who experienced meaningful weight loss and metabolic progress—suggesting the benefits may be tied to overall health gains, not just the medication itself.
“This data suggests these medications do not harm mental health and may even provide added benefits for people struggling with substance use,” Jakobi said. “While patients should always be monitored closely, the results may support broader and more confident use of these treatments.”
Mobile Sidebar Ad
Why Researchers Are Looking at the Brain
The connection between GLP-1 medications and mental health is not entirely surprising to researchers.
Dr. Todd Worley, an obesity medicine specialist and bariatric surgeon at Houston Methodist Willowbrook Hospital, said the science points to a deeper biological link.
“There are GLP-1 receptors in the brain, so it’s reasonable to explore whether these medications could help with conditions like depression, anxiety or substance use disorder,” Worley said. “This study doesn’t prove that connection, but there’s enough positive data to justify further research.”
The Lancet study supports that idea, noting that GLP-1 medications may influence brain pathways related to mood, behavior, and inflammation, while also improving metabolic health—factors that are often closely connected.
Beyond the Scale: Real-World Impacts on Daily Life
For many patients, the implications go beyond clinical outcomes.
Worley pointed to additional findings suggesting fewer hospitalizations and fewer missed workdays among people taking GLP-1 medications—changes that can have meaningful effects on quality of life, family stability, and productivity.
In communities like Houston, where access to care, chronic disease management, and mental health support are ongoing priorities, those ripple effects carry real weight for families. In Harris County, an estimated 37.3% of adults are living with obesity, notably higher than the national average of 32.8%, according to the CDC’s PLACES data.
That same data shows how closely obesity is tied to broader health challenges in the region—13.2% of adults have been diagnosed with diabetes, while nearly one-third live with high blood pressure, both conditions commonly linked to excess weight.
At the same time, the connection between physical and mental health is hard to ignore. In Harris County, about 1 in 5 adults reports experiencing depression, and more than 16% report frequent mental distress, reinforcing what health experts have long observed: physical health and mental well-being often move together, not separately.
A Growing Presence in Houston’s Health Landscape
The timing of this research is especially relevant locally, as Houston welcomes a new GLP-1 manufacturing facility, signaling continued growth in both availability and demand.
With more residents exploring options like semaglutide (commonly known through brand names such as Ozempic and Wegovy), conversations around safety, long-term effects, and overall wellness are becoming more common in clinics and households alike.
Mobile Sidebar Ad
What Patients Should Keep in Mind
While the findings are encouraging, experts emphasize the importance of individualized care.
Both Jakobi and Worley stress that patients should work closely with their healthcare providers to monitor both physical and mental health while using GLP-1 medications.
The study itself highlights the need for additional long-term research, particularly randomized controlled trials, to better understand how these medications interact with mental health over time .
What Happens Next
As research continues, GLP-1 medications are likely to remain at the center of conversations around weight loss, diabetes care, and now, mental health.
For Houston-area patients and families, the latest findings offer a clearer picture—one that suggests these treatments may support overall well-being more broadly than previously understood.
Still, as with any evolving medical breakthrough, the next chapter will be shaped by ongoing research, patient experiences, and the guidance of local healthcare providers.
Residents looking to learn more about weight loss medications and treatment options can visit Houston Methodist’s website for additional resources.
For continued coverage on health developments impacting Houston-area communities, stay connected with My Neighborhood News.
Tiffany Krenek has been on the My Neighborhood News team since August 2021. She is passionate about curating and sharing content that enriches the lives of our readers in a personal, meaningful way. A loving mother and wife, Tiffany and her family live in the West Houston/Cypress region.